Immediate Salvage Radiation Therapy Should Be Initiated
For a patient with PSA levels of 0.7-0.8 ng/mL after radical prostatectomy, you should initiate salvage radiation therapy (SRT) immediately, and strongly consider adding androgen deprivation therapy (ADT) given these PSA values meet high-risk criteria. 1, 2
Treatment Algorithm
1. Salvage Radiation Therapy - Initiate Now
Your patient's PSA levels of 0.7-0.8 ng/mL fall into a critical treatment window:
- The 2024 AUA/ASTRO/SUO guidelines provide a moderate recommendation to deliver salvage RT when PSA is ≤ 0.5 ng/mL 1
- While your patient exceeds this threshold, they remain well below the 1.0 ng/mL cutoff where outcomes significantly worsen
- Data from 1,108 patients showed 5-year biochemical failure rates of:
- 26.6% when PSA < 0.2 ng/mL
- 32.7% when PSA 0.21-0.50 ng/mL
- 37.8% when PSA 0.51-1.0 ng/mL (your patient's range)
- 57% when PSA > 1.0-2.0 ng/mL 1
Every delay worsens outcomes. Pre-salvage RT PSA level was the strongest predictor of secondary biochemical failure, metastatic progression-free survival, and prostate cancer-specific mortality 1.
2. Add Androgen Deprivation Therapy
You should offer ADT in addition to salvage RT because PSA ≥ 0.7 ng/mL is explicitly defined as a high-risk feature warranting combined therapy 2:
- The 2024 guidelines provide a moderate recommendation (Grade B evidence) for ADT addition when PSA ≥ 0.7 ng/mL 2
- Three randomized trials (GETUG-AFU 16, RTOG 9601, NRG/RTOG 0534) demonstrated:
- Improved progression-free survival (64% vs 49% at 10 years)
- Improved metastasis-free survival (75% vs 69%)
- Reduced prostate cancer-specific mortality (5.8% vs 13.4% at 12 years) 2
3. Other High-Risk Features to Assess
Before finalizing the treatment plan, verify if your patient has additional high-risk features that further support ADT use 2:
- Gleason Grade Group 4-5 (critical prognostic factor)
- PSA doubling time ≤ 6 months (calculate if serial PSAs available)
- Seminal vesicle involvement on pathology
- Positive surgical margins (R1/R2 status)
- Pathologic stage T3-4
The presence of any of these features strengthens the indication for combined SRT + ADT.
4. ADT Duration
Based on trial data 2:
- Short-term ADT: 4-6 months is effective and reduces long-term side effects
- GETUG-AFU 16 used 6 months successfully
- Consider longer duration (up to 24 months) only if multiple high-risk features present
Critical Pitfalls to Avoid
Do not wait for PSA to rise further. The most common error is delaying treatment:
- Patients treated at PSA > 1.0 ng/mL have nearly double the biochemical failure rate compared to those treated at 0.5-1.0 ng/mL 1
- Prostate cancer-specific mortality increases significantly (6% vs 13% at 10 years) when salvage RT is delayed beyond PSA 0.5 ng/mL 1
Do not omit ADT based solely on the PSA threshold. While some data suggest 0.35 ng/mL as an alternative threshold, your patient at 0.7-0.8 ng/mL clearly meets the established high-risk criterion 2.
Do not order extensive imaging to delay treatment unless it will change management. Modern imaging (PSMA PET) may identify oligometastatic disease, but in the absence of symptoms or very rapid PSA kinetics, proceed with salvage therapy.
Supporting Evidence for Lower PSA Thresholds
Emerging research suggests even earlier intervention may be beneficial 3, 4:
- First postoperative ultrasensitive PSA ≥ 0.03 ng/mL independently predicts worse biochemical recurrence-free survival, bone metastasis-free survival, and overall survival 4
- High-risk patients with PSA ≥ 0.03 ng/mL had median time to recurrence of only 1.1 years 3
However, guideline-based thresholds remain the standard of care, and your patient's PSA levels clearly exceed all established treatment thresholds.
Quality of Life Considerations
Salvage RT with short-term ADT has minimal impact on quality of life:
- SF-6D scores showed no significant difference between screened and control groups (0.777 vs 0.779) 5
- Short-term ADT (4-6 months) causes temporary side effects (hot flashes, fatigue, decreased libido) that resolve after completion
- The alternative—allowing disease progression—results in far worse quality of life from metastatic disease and its treatments